Results of cross-linking for corneal melting disorders

Article

Results of cross-linking for corneal melting disorders

Corneal cross-linking (CXL) can help treat corneal melting, Dr. Theo Seiler told delegates at the ESCRS Congress.

Riboflavin and UVA creates additional chemical bonds within the collagen molecule and, most probably, between adjacent collagen molecules, he remarked.

Such cross-links reduce the docking sites on the collagen molecule available to collagenases, Dr. Seiler noted. “Early clinical results of CXL and corneal melting were published in 2000 by Schnitzler et al, and in three out of four cases the melting was stopped.”

Dr. Seiler related an elegant experiment by Wollensak, where pieces of pig cornea, one cross-linked and one not, were put in a solution of collegenases. The cross linked cornea dissolved unevenly. The surface, where the cross-linking had an effect, resisted dissolution.

The normal cornea, on the other hand, dissolved evenly, demonstrating that collegenases had a much smaller effect on the cross-linked cornea.

Dr. Seiler revealed that his clinic had six cases of therapy-refractory corneal melting. “Three cases related to infection, there was 1 case each of Mb Terrien and Mb. Sjogren, and 1 case after LASIK.”

In all cases melting stopped after cross-linking. “Additional therapies were applied for the cases relating to infection, LASIK and Mb Sjogren,” he stated, though no additional therapy was pursued for the Mb Terrien.

In the cases of infection, additional therapies included PKP, ALKP and PRK. The LASIK case was additionally treated with DLKP while the Sjogren received ALKP.

Dr. Seiler concluded that CXL is an interesting option in cases of corneal melting. “It appears to be effective, but its safety is not clear. We observed corneal thickening after CXL in Mb Terrien, but this is just one observation and needs to be confirmed.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.